Selected research
Market Analysis & Forecast
Global Drug Release Platform Market Analysis and Forecast 2026-2032
Market perspective
The global Drug Release Platform market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Drug Release Platform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Drug Release Platform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Drug Release Platform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Drug Release Platform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Drug Release Platform include Evonik, Camurus, Pacira BioSciences, Starpharma, ProLynx, Liquidia, MedinCell, Intarcia and Corium, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Drug Release Platform, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Drug Release Platform, also provides the revenue of main regions and countries. Of the upcoming market potential for Drug Release Platform, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Drug Release Platform revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drug Release Platform market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Drug Release Platform revenue, projected growth trends, production technology, application and end-user industry.
Drug Release Platform Segment by Company
Evonik
Camurus
Pacira BioSciences
Starpharma
ProLynx
Liquidia
MedinCell
Intarcia
Corium
Enable Injections
Alkermes
Depomed
NanoCarrier
Lyndra
Hisun Pharmaceutical
Livzon Pharmaceutical Group
Hengrui Pharmaceuticals
HEC ChangJiang Pharmaceutical
Luye Pharma
Lanna Bio
Drug Release Platform Segment by Type
Oral Sustained-Release Platform
Implantable Sustained-Release Platform
Local Sustained-Release Platform
Drug Release Platform Segment by Application
Pharmaceutical Companies
Hospitals
Others
Drug Release Platform Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Release Platform market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drug Release Platform and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Release Platform.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Drug Release Platform in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Drug Release Platform company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drug Release Platform revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral Sustained-Release Platform
- Implantable Sustained-Release Platform
- Local Sustained-Release Platform
Applications
- Pharmaceutical Companies
- Hospitals
- Others
Companies covered
- Evonik
- Camurus
- Pacira BioSciences
- Starpharma
- ProLynx
- Liquidia
- MedinCell
- Intarcia
- Corium
- Enable Injections
- Alkermes
- Depomed
- NanoCarrier
- Lyndra
- Hisun Pharmaceutical
- Livzon Pharmaceutical Group
- Hengrui Pharmaceuticals
- HEC ChangJiang Pharmaceutical
- Luye Pharma
- Lanna Bio
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Drug Release Platform Market by Type
- 1.2.1 Global Drug Release Platform Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Oral Sustained-Release Platform
- 1.2.3 Implantable Sustained-Release Platform
- 1.2.4 Local Sustained-Release Platform
- 1.3 Drug Release Platform Market by Application
- 1.3.1 Global Drug Release Platform Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Pharmaceutical Companies
- 1.3.3 Hospitals
- 1.3.4 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Drug Release Platform Market Dynamics
- 2.1 Drug Release Platform Industry Trends
- 2.2 Drug Release Platform Industry Drivers
- 2.3 Drug Release Platform Industry Opportunities and Challenges
- 2.4 Drug Release Platform Industry Restraints
3 Global Growth Perspective
- 3.1 Global Drug Release Platform Market Perspective (2021-2032)
- 3.2 Global Drug Release Platform Growth Trends by Region
- 3.2.1 Global Drug Release Platform Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Drug Release Platform Market Size by Region (2021-2026)
- 3.2.3 Global Drug Release Platform Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Drug Release Platform Revenue by Players
- 4.1.1 Global Drug Release Platform Revenue by Players (2021-2026)
- 4.1.2 Global Drug Release Platform Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Drug Release Platform Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Drug Release Platform Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Drug Release Platform Key Players Headquarters & Area Served
- 4.4 Global Drug Release Platform Players, Product Type & Application
- 4.5 Global Drug Release Platform Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Drug Release Platform Market CR5 and HHI
- 4.6.3 2025 Drug Release Platform Tier 1, Tier 2, and Tier 3
5 Drug Release Platform Market Size by Type
- 5.1 Global Drug Release Platform Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Drug Release Platform Revenue by Type (2021-2032)
- 5.3 Global Drug Release Platform Revenue Market Share by Type (2021-2032)
6 Drug Release Platform Market Size by Application
- 6.1 Global Drug Release Platform Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Drug Release Platform Revenue by Application (2021-2032)
- 6.3 Global Drug Release Platform Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Evonik
- 7.1.1 Evonik Company Information
- 7.1.2 Evonik Business Overview
- 7.1.3 Evonik Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.1.4 Evonik Drug Release Platform Product Portfolio
- 7.1.5 Evonik Recent Developments
- 7.2 Camurus
- 7.2.1 Camurus Company Information
- 7.2.2 Camurus Business Overview
- 7.2.3 Camurus Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.2.4 Camurus Drug Release Platform Product Portfolio
- 7.2.5 Camurus Recent Developments
- 7.3 Pacira BioSciences
- 7.3.1 Pacira BioSciences Company Information
- 7.3.2 Pacira BioSciences Business Overview
- 7.3.3 Pacira BioSciences Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.3.4 Pacira BioSciences Drug Release Platform Product Portfolio
- 7.3.5 Pacira BioSciences Recent Developments
- 7.4 Starpharma
- 7.4.1 Starpharma Company Information
- 7.4.2 Starpharma Business Overview
- 7.4.3 Starpharma Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.4.4 Starpharma Drug Release Platform Product Portfolio
- 7.4.5 Starpharma Recent Developments
- 7.5 ProLynx
- 7.5.1 ProLynx Company Information
- 7.5.2 ProLynx Business Overview
- 7.5.3 ProLynx Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.5.4 ProLynx Drug Release Platform Product Portfolio
- 7.5.5 ProLynx Recent Developments
- 7.6 Liquidia
- 7.6.1 Liquidia Company Information
- 7.6.2 Liquidia Business Overview
- 7.6.3 Liquidia Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.6.4 Liquidia Drug Release Platform Product Portfolio
- 7.6.5 Liquidia Recent Developments
- 7.7 MedinCell
- 7.7.1 MedinCell Company Information
- 7.7.2 MedinCell Business Overview
- 7.7.3 MedinCell Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.7.4 MedinCell Drug Release Platform Product Portfolio
- 7.7.5 MedinCell Recent Developments
- 7.8 Intarcia
- 7.8.1 Intarcia Company Information
- 7.8.2 Intarcia Business Overview
- 7.8.3 Intarcia Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.8.4 Intarcia Drug Release Platform Product Portfolio
- 7.8.5 Intarcia Recent Developments
- 7.9 Corium
- 7.9.1 Corium Company Information
- 7.9.2 Corium Business Overview
- 7.9.3 Corium Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.9.4 Corium Drug Release Platform Product Portfolio
- 7.9.5 Corium Recent Developments
- 7.10 Enable Injections
- 7.10.1 Enable Injections Company Information
- 7.10.2 Enable Injections Business Overview
- 7.10.3 Enable Injections Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.10.4 Enable Injections Drug Release Platform Product Portfolio
- 7.10.5 Enable Injections Recent Developments
- 7.11 Alkermes
- 7.11.1 Alkermes Company Information
- 7.11.2 Alkermes Business Overview
- 7.11.3 Alkermes Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.11.4 Alkermes Drug Release Platform Product Portfolio
- 7.11.5 Alkermes Recent Developments
- 7.12 Depomed
- 7.12.1 Depomed Company Information
- 7.12.2 Depomed Business Overview
- 7.12.3 Depomed Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.12.4 Depomed Drug Release Platform Product Portfolio
- 7.12.5 Depomed Recent Developments
- 7.13 NanoCarrier
- 7.13.1 NanoCarrier Company Information
- 7.13.2 NanoCarrier Business Overview
- 7.13.3 NanoCarrier Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.13.4 NanoCarrier Drug Release Platform Product Portfolio
- 7.13.5 NanoCarrier Recent Developments
- 7.14 Lyndra
- 7.14.1 Lyndra Company Information
- 7.14.2 Lyndra Business Overview
- 7.14.3 Lyndra Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.14.4 Lyndra Drug Release Platform Product Portfolio
- 7.14.5 Lyndra Recent Developments
- 7.15 Hisun Pharmaceutical
- 7.15.1 Hisun Pharmaceutical Company Information
- 7.15.2 Hisun Pharmaceutical Business Overview
- 7.15.3 Hisun Pharmaceutical Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.15.4 Hisun Pharmaceutical Drug Release Platform Product Portfolio
- 7.15.5 Hisun Pharmaceutical Recent Developments
- 7.16 Livzon Pharmaceutical Group
- 7.16.1 Livzon Pharmaceutical Group Company Information
- 7.16.2 Livzon Pharmaceutical Group Business Overview
- 7.16.3 Livzon Pharmaceutical Group Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.16.4 Livzon Pharmaceutical Group Drug Release Platform Product Portfolio
- 7.16.5 Livzon Pharmaceutical Group Recent Developments
- 7.17 Hengrui Pharmaceuticals
- 7.17.1 Hengrui Pharmaceuticals Company Information
- 7.17.2 Hengrui Pharmaceuticals Business Overview
- 7.17.3 Hengrui Pharmaceuticals Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.17.4 Hengrui Pharmaceuticals Drug Release Platform Product Portfolio
- 7.17.5 Hengrui Pharmaceuticals Recent Developments
- 7.18 HEC ChangJiang Pharmaceutical
- 7.18.1 HEC ChangJiang Pharmaceutical Company Information
- 7.18.2 HEC ChangJiang Pharmaceutical Business Overview
- 7.18.3 HEC ChangJiang Pharmaceutical Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.18.4 HEC ChangJiang Pharmaceutical Drug Release Platform Product Portfolio
- 7.18.5 HEC ChangJiang Pharmaceutical Recent Developments
- 7.19 Luye Pharma
- 7.19.1 Luye Pharma Company Information
- 7.19.2 Luye Pharma Business Overview
- 7.19.3 Luye Pharma Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.19.4 Luye Pharma Drug Release Platform Product Portfolio
- 7.19.5 Luye Pharma Recent Developments
- 7.20 Lanna Bio
- 7.20.1 Lanna Bio Company Information
- 7.20.2 Lanna Bio Business Overview
- 7.20.3 Lanna Bio Drug Release Platform Revenue and Gross Margin (2021-2026)
- 7.20.4 Lanna Bio Drug Release Platform Product Portfolio
- 7.20.5 Lanna Bio Recent Developments
8 North America
- 8.1 North America Drug Release Platform Revenue (2021-2032)
- 8.2 North America Drug Release Platform Revenue by Type (2021-2032)
- 8.2.1 North America Drug Release Platform Revenue by Type (2021-2026)
- 8.2.2 North America Drug Release Platform Revenue by Type (2027-2032)
- 8.3 North America Drug Release Platform Revenue Share by Type (2021-2032)
- 8.4 North America Drug Release Platform Revenue by Application (2021-2032)
- 8.4.1 North America Drug Release Platform Revenue by Application (2021-2026)
- 8.4.2 North America Drug Release Platform Revenue by Application (2027-2032)
- 8.5 North America Drug Release Platform Revenue Share by Application (2021-2032)
- 8.6 North America Drug Release Platform Revenue by Country
- 8.6.1 North America Drug Release Platform Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Drug Release Platform Revenue by Country (2021-2026)
- 8.6.3 North America Drug Release Platform Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Drug Release Platform Revenue (2021-2032)
- 9.2 Europe Drug Release Platform Revenue by Type (2021-2032)
- 9.2.1 Europe Drug Release Platform Revenue by Type (2021-2026)
- 9.2.2 Europe Drug Release Platform Revenue by Type (2027-2032)
- 9.3 Europe Drug Release Platform Revenue Share by Type (2021-2032)
- 9.4 Europe Drug Release Platform Revenue by Application (2021-2032)
- 9.4.1 Europe Drug Release Platform Revenue by Application (2021-2026)
- 9.4.2 Europe Drug Release Platform Revenue by Application (2027-2032)
- 9.5 Europe Drug Release Platform Revenue Share by Application (2021-2032)
- 9.6 Europe Drug Release Platform Revenue by Country
- 9.6.1 Europe Drug Release Platform Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Drug Release Platform Revenue by Country (2021-2026)
- 9.6.3 Europe Drug Release Platform Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Drug Release Platform Revenue (2021-2032)
- 10.2 China Drug Release Platform Revenue by Type (2021-2032)
- 10.2.1 China Drug Release Platform Revenue by Type (2021-2026)
- 10.2.2 China Drug Release Platform Revenue by Type (2027-2032)
- 10.3 China Drug Release Platform Revenue Share by Type (2021-2032)
- 10.4 China Drug Release Platform Revenue by Application (2021-2032)
- 10.4.1 China Drug Release Platform Revenue by Application (2021-2026)
- 10.4.2 China Drug Release Platform Revenue by Application (2027-2032)
- 10.5 China Drug Release Platform Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Drug Release Platform Revenue (2021-2032)
- 11.2 Asia Drug Release Platform Revenue by Type (2021-2032)
- 11.2.1 Asia Drug Release Platform Revenue by Type (2021-2026)
- 11.2.2 Asia Drug Release Platform Revenue by Type (2027-2032)
- 11.3 Asia Drug Release Platform Revenue Share by Type (2021-2032)
- 11.4 Asia Drug Release Platform Revenue by Application (2021-2032)
- 11.4.1 Asia Drug Release Platform Revenue by Application (2021-2026)
- 11.4.2 Asia Drug Release Platform Revenue by Application (2027-2032)
- 11.5 Asia Drug Release Platform Revenue Share by Application (2021-2032)
- 11.6 Asia Drug Release Platform Revenue by Country
- 11.6.1 Asia Drug Release Platform Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Drug Release Platform Revenue by Country (2021-2026)
- 11.6.3 Asia Drug Release Platform Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Drug Release Platform Revenue (2021-2032)
- 12.2 SAMEA Drug Release Platform Revenue by Type (2021-2032)
- 12.2.1 SAMEA Drug Release Platform Revenue by Type (2021-2026)
- 12.2.2 SAMEA Drug Release Platform Revenue by Type (2027-2032)
- 12.3 SAMEA Drug Release Platform Revenue Share by Type (2021-2032)
- 12.4 SAMEA Drug Release Platform Revenue by Application (2021-2032)
- 12.4.1 SAMEA Drug Release Platform Revenue by Application (2021-2026)
- 12.4.2 SAMEA Drug Release Platform Revenue by Application (2027-2032)
- 12.5 SAMEA Drug Release Platform Revenue Share by Application (2021-2032)
- 12.6 SAMEA Drug Release Platform Revenue by Country
- 12.6.1 SAMEA Drug Release Platform Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Drug Release Platform Revenue by Country (2021-2026)
- 12.6.3 SAMEA Drug Release Platform Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst